GlassScriptPhysician profile
Michael S Curtis
NPI 1336280759
$7,911.58
in general payments reported to CMS, 2019-2025
63 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $998 · 2021: $1,479 · 2022: $1,056 · 2023: $1,163 · 2024: $1,196 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,430.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,267.55 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,196.36 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $412.18 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astellas Pharma US INC | $307.33 | 2019-2025 | Veozah |
| Amgen INC. | $301.03 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $298.06 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $291.29 | 2020-2023 | Austedo |
| Sanofi-Aventis U.S. LLC | $257.30 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $245.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $240.13 | 2019-2022 | |
| Novo Nordisk INC | $227.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $226.48 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $186.15 | 2019-2021 | |
| Mylan Specialty L.P. | $162.57 | 2020-2024 | Yupelri |
| Impel Pharmaceuticals INC. | $160.00 | 2022-2023 | Trudhesa |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $156.19 | 2021-2025 | Qelbree |
| Abbott Laboratories | $135.16 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.48 | 2019-2021 | |
| Boston Scientific Corporation | $96.85 | 2019-2023 | Watchman Access System |
| Biohaven Pharmaceuticals, INC. | $90.45 | 2021 | |
| Grifols USA, LLC | $87.88 | 2023-2025 | Prolastin-C Liquid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.11 | 2019-2022 | |
| Edwards Lifesciences Corporation | $74.86 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $73.84 | 2020-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Bausch Health US, LLC | $69.06 | 2021-2024 | Aplenzin |
| Biohaven Pharmaceutical Holding Company LTD. | $67.25 | 2022 | |
| Viatris Specialty LLC | $61.24 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $60.94 | 2025 | Voquezna |
| Ironshore Pharmaceuticals INC. | $59.96 | 2019-2023 | Jornay Pm |
| Mannkind Corporation | $52.99 | 2020-2021 | |
| Corium, LLC | $52.26 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $47.20 | 2024-2025 | Auvelity, Sunosi |
| Cranial Technologies, INC | $47.15 | 2019-2024 | Doc Band |
| Upsher-Smith Laboratories LLC | $46.15 | 2021 | |
| Dynavax Technologies Corporation | $44.27 | 2020-2023 | Heplisav-B |
| Nestle Healthcare Nutrition INC. | $44.22 | 2021-2022 | |
| Tris Pharma INC | $38.52 | 2019-2023 | Dyanavel Xr |
| Daiichi Sankyo INC. | $37.93 | 2021 | |
| Neurocrine Biosciences, INC. | $31.47 | 2024-2025 | Ingrezza |
| Lucid Diagnostics INC. | $30.93 | 2023 | |
| Medtronic, INC. | $29.78 | 2024-2025 | Venaseal |
| Janssen Pharmaceuticals, INC | $28.57 | 2025 | Spravato |
| Nevro Corp. | $27.75 | 2024 | Senza |
| Alkermes, INC. | $26.31 | 2023 | Lybalvi |
| Neuronetics, INC. | $22.80 | 2025 | Neurostar Tms Therapy System |
| Smith+Nephew, INC. | $21.47 | 2025 | Grafix Pl |
| Indivior INC. | $20.57 | 2024 | Sublocade |
| Phadia US INC. | $20.17 | 2023 | Immunocap |
| Organon LLC | $19.72 | 2022-2023 | Nexplanon |
| Idorsia Pharmaceuticals US INC | $18.45 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $18.19 | 2023 | |
| Neurelis, INC. | $16.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.19 | 2023 | Seglentis, Livalo |
| Strongbridge US INC. | $15.85 | 2019 | |
| Genentech USA, INC. | $15.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.33 | 2023 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.55 | 2025 | Caplyta |
| C. R. Bard, INC. & Subsidiaries | $14.17 | 2024 | Bd Onclarity |
| Qiagen, LLC | $13.75 | 2021 | |
| Alfasigma USA, INC. | $13.45 | 2020 | |
| Pear Therapeutics (US), INC. | $13.19 | 2022 | |
| Sobi, INC | $13.15 | 2021 | |
| Eisai INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.